直接口服抗凝药在儿科人群中的有效性和安全性:系统评价与Meta分析
该系统评价与Meta分析检索MEDLINE、EMBASE和ClinicalTrials.gov至2022年8月20日,纳入7项随机对照试验(6项进入Meta分析),比较直接口服抗凝药(DOACs)与标准治疗在18岁以下人群中的有效性和安全性;结果显示治疗场景下DOACs显著降低静脉血栓栓塞复发(OR=0.42,95%CI 0.19-0.94),预防场景下无显著差异,安全性总体无重大 issues。
要点
- 治疗静脉血栓栓塞时DOACs较标准治疗显著降低复发(OR=0.42,95%CI 0.19-0.94)。
- 心脏疾病预防场景下DOACs对静脉血栓栓塞发生无显著降低(OR=0.22,95%CI 0.03-1.55)。
- 治疗场景下因不良事件停药显著增加,其余安全性终点无显著差异或仅呈非显著趋势。
核心结论
- 在儿科人群中,DOAC治疗较标准治疗似乎可降低静脉血栓栓塞且无重大安全性问题,而DOAC预防至少与标准治疗相当。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE(PubMed)、EMBASE和ClinicalTrials.gov从建库至2022年8月20日,纳入7项随机对照试验(其中6项进入Meta分析:3项心脏疾病预防和3项静脉血栓栓塞治疗),研究对象为18岁以下患者。
主要发现
- 治疗场景下DOACs较标准治疗显著降低静脉血栓栓塞复发(OR=0.42;95%CI 0.19-0.94)。
- 预防场景下DOACs对静脉血栓栓塞发生的降低无统计学显著性(OR=0.22;95%CI 0.03-1.55)。
- 预防场景下任何出血、严重不良事件和重大出血均无差异。
- 治疗场景下临床相关非重大出血和重大出血、预防场景下因不良事件停药均呈非显著趋势。
- 治疗场景下因不良事件停药显著增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Direct oral anticoagulants (DOACs) represent a cornerstone of adult venous thromboembolism (VTE) treatment. Recently, randomized controlled trials (RCTs) investigating DOACs in pediatrics have been performed. OBJECTIVES: To evaluate the efficacy and safety of DOACs in the pediatric population. METHODS: We systematically searched MEDLINE (PubMed), EMBASE, and ClinicalTrials.gov from initiation up to August 20, 2022, for RCTs comparing DOACs to standard of care (SOC) in patients aged <18 years according to PRISMA guidelines (PROSPERO registration CRD42022353870). The primary analysis was performed according to the anticoagulation intensity and clinical setting (ie, prophylaxis in cardiac disease or treatment in VTE). Efficacy outcomes were all-cause mortality and VTE. Safety outcomes were major bleeding (MB), clinically relevant non-MB, any bleeding, serious adverse events, and discontinuation due to adverse events (AEs). RESULTS: Seven RCTs were included in the systematic review and 6 in the meta-analysis (3 prophylaxis in cardiac disease and 3 treatment in VTE). DOACs showed a significant reduction of VTE recurrence for treatment (odds ratio [OR] = 0.42; 95% CI, 0.19-0.94) and a nonsignificant reduction in VTE occurrence in prophylaxis (OR = 0.22; 95% CI, 0.03-1.55). No differences were observed for any bleeding, serious AEs, and MB in prophylaxis. Nonsignificant trends were observed for clinically relevant non-MB, MB in treatment, and discontinuation due to AE in prophylaxis. We found a significant increase in discontinuation due to AE in treatment. CONCLUSIONS: DOAC treatment seems to reduce VTE compared with SOC without major safety issues in the pediatric population, whereas DOAC prophylaxis seems at least comparable to SOC.
引用
- Giossi R, Menichelli D, D'Amico F, et al. Efficacy and safety of direct oral anticoagulants in the pediatric population: a systematic review and a meta-analysis. J Thromb Haemost. 2023. PMID: 37481075. doi:10.1016/j.jtha.2023.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。